Abstract:When the one-stage clotting assay is used in comparison with the chromogenic and immunological assays, plasma levels of factor (F)VIII are underestimated by 40-50% after infusion of B-domain deleted recombinant FVIII (BDD-rFVIII) in patients with hemophilia. A possible way to counteract the underestimation of FVIII levels by the one-stage assay is the adoption of a recombinant FVIII reference standard instead of a plasma standard. To evaluate the usefulness of such a standard [ReFacto Laboratory Standard (RLS)], the pharmacokinetic parameters of a single dose of BDD-rFVIII (25 U kg(-1)) were evaluated in a multicenter study carried out in 18 patients with severe hemophilia A. The very low in vivo recovery, obtained with the combination of the one-stage assay and plasma reference standard, was increased up to the values obtained by the chromogenic assay when the results were expressed in terms of RLS. When the plasma standard was used, the one-stage/chromogenic ratio was 0.82 +/- 0.12 for FVIII levels above 25 U dL(-1) and 1.42 +/- 0.99 for FVIII levels below 25 U dL(-1). Using the RLS, the one-stage/chromogenic ratio increased to 1.01 +/- 0.19 at FVIII levels above 25 U dL(-1), as a consequence of a complete overlap of the two decays; however, at FVIII levels below 25 U dL(-1), the one-stage/chromogenic ratio was still 1.6 +/- 0.85. After the twelfth hour, FVIII concentrations obtained by chromogenic assay were always lower than those resulting from the one-stage clotting assay, independently of the standard used. Results obtained by chromogenic assay were not affected by the type of standard used. Compared with those obtained by the one-stage assay, higher values of clearance, lower volume of distribution area and shorter plasma half-life or mean residence time were obtained by chromogenic assay because of a shape change of the decay curve due to a shift to higher values in the first part (time interval 0-12 h) and to lower values in the second part of the decay curve (time interval 12-48 h). As a consequence, the slope of the decay curve obtained by means of chromogenic assay was steeper. In conclusion, the more homogeneous results of in vivo recovery and pharmacokinetic analysis, due to the decrease of discrepancy between the two methods when RLS was used, make the cheaper and more widely used one-stage assay preferable to the more expensive chromogenic assay, on condition that the ReFacto specific standard has used.

Multicenter performance evaluation and reference range determination of a new one-stage factor VIII assay

Comparative field study: impact of laboratory assay variability on the assessment of recombinant factor IX Fc fusion protein (rFIXFc) activity

Accurate measurement of extended half-life and unmodified factor VIII low levels with one-stage FVIII assays is dependent on the matrix of calibration curves

Expert systems: robot physicians of the future?

A multicenter pharmacokinetic study of the B-domain deleted recombinant factor VIII concentrate using different assays and standards

Comparison of several von Willebrand factor (VWF) activity assays for monitoring patients undergoing treatment with VWF/FVIII concentrates: improved performance with a new modified automated method.

A-160 Factor VIII Chromogenic Low Activity Sample Analysis in a Low Calibration Curve Model

Clinical Validation of an Automated Fluorogenic Factor XIII Activity Assay Based on Isopeptidase Activity

Removable partial denture abutments restored with all-ceramic surveyed crowns.

Area under the curve: Comparing the value of factor VIII replacement therapies in haemophilia A

Proposal for Objective Evaluation of the Performance of Various Functional APC-resistance Tests in Genotyped Patients

Performance Evaluation of Clinical Detection of Coagulation Factors, Protein S, Protein C, Anti-thrombin Ⅲ, and von Willebrand Factor Antigen

Interleukin-10 gene polymorphism in patients with papillary thyroid cancer in Turkish population

Auto-rickshaw: an automated crystal structure determination platform as an efficient tool for the validation of an X-ray diffraction experiment.

Comprehensive laboratory assessment of lonoctocog alfa versus octocog alfa in severe haemophilia A

Coagulation factors VIII and factors IX testing practices in China: Results of the 5-year external quality assessment program

Commercial human frozen plasmas for local, cross-site and long-term comparability of coagulation analysers

Isolation of a novel menaquinone with a partly hydrogenated side chain from Propionibacterium arabinosum.

Comparison of the Pharmacokinetic Properties of Extended Half-Life and Recombinant Factor VIII Concentrates by In Silico Simulations

GB virus type C coinfection in HIV-infected African mothers and their infants, KwaZulu Natal, South Africa.

Variability in combinations of APTT reagent and substrate plasma for a one‐stage clotting assay to measure factor VIII products